Generic placeholder image

Cardiovascular & Hematological Disorders-Drug Targets

Author(s): Fernando Segovia*, Hernando Garcia, Haider Alkhateeb, Debabrata Mukherjee and Nils Nickel

DOI: 10.2174/011871529X258234230921112507

DownloadDownload PDF Flyer Cite As
Updates in the Pharmacotherapy of Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction

Page: [215 - 225] Pages: 11

  • * (Excluding Mailing and Handling)

Abstract

Pulmonary hypertension (PH) associated with left heart disease (LHD) is a complex cardiopulmonary condition where a variable degree of pulmonary congestion, arterial vasoconstriction and vascular remodeling can lead to PH and right heart strain. Right heart dysfunction has a significant prognostic impact on these patients. Therefore, preserving right ventricular (RV) function is an important treatment goal. However, the treatment of PH in patients with left heart disease has produced conflicting evidence. The transition from pure LHD to LHD with PH is a continuum and clinically challenging. The heart failure with preserved ejection fraction (HFpEF) patient population is heterogeneous when it comes to PH and RV function. Appropriate clinical and hemodynamic phenotyping of patients with HFpEF and concomitant PH is paramount to making the appropriate treatment decision. This manuscript will summarize the current evidence for the use of pulmonary arterial vasodilators in patients with HFpEF.

Graphical Abstract

[1]
McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O.; Cleland, J.G.F.; Coats, A.J.S.; Crespo-Leiro, M.G.; Farmakis, D.; Gilard, M.; Heymans, S.; Hoes, A.W.; Jaarsma, T.; Jankowska, E.A.; Lainscak, M.; Lam, C.S.P.; Lyon, A.R.; McMurray, J.J.V.; Mebazaa, A.; Mindham, R.; Muneretto, C.; Francesco Piepoli, M.; Price, S.; Rosano, G.M.C.; Ruschitzka, F.; Kathrine Skibelund, A. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. J. Heart Fail., 2022, 24(1), 4-131.
[http://dx.doi.org/10.1002/ejhf.2333] [PMID: 35083827]
[2]
Klinger, J.R.; Elliott, C.G.; Levine, D.J.; Bossone, E.; Duvall, L.; Fagan, K.; Frantsve-Hawley, J.; Kawut, S.M.; Ryan, J.J.; Rosenzweig, E.B.; Sederstrom, N.; Steen, V.D.; Badesch, D.B. Therapy for pulmonary arterial hypertension in adults. Chest, 2019, 155(3), 565-586.
[http://dx.doi.org/10.1016/j.chest.2018.11.030] [PMID: 30660783]
[3]
McLaughlin, V.V.; Archer, S.L.; Badesch, D.B.; Barst, R.J.; Farber, H.W.; Lindner, J.R.; Mathier, M.A.; McGoon, M.D.; Park, M.H.; Rosenson, R.S.; Rubin, L.J.; Tapson, V.F.; Varga, J. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. J. Am. Coll. Cardiol., 2009, 53(17), 1573-1619.
[http://dx.doi.org/10.1016/j.jacc.2009.01.004] [PMID: 19389575]
[4]
Rosenkranz, S.; Gibbs, J.S.R.; Wachter, R.; De Marco, T.; Vonk-Noordegraaf, A.; Vachiéry, J.L. Left ventricular heart failure and pulmonary hypertension. Eur. Heart J., 2016, 37(12), 942-954.
[http://dx.doi.org/10.1093/eurheartj/ehv512] [PMID: 26508169]
[5]
Maron, B.A.; Brittain, E.L.; Hess, E.; Waldo, S.W.; Barón, A.E.; Huang, S.; Goldstein, R.H.; Assad, T.; Wertheim, B.M.; Alba, G.A.; Leopold, J.A.; Olschewski, H.; Galiè, N.; Simonneau, G.; Kovacs, G.; Tedford, R.J.; Humbert, M.; Choudhary, G. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir. Med., 2020, 8(9), 873-884.
[http://dx.doi.org/10.1016/S2213-2600(20)30317-9] [PMID: 32730752]
[6]
Caravita, S.; Dewachter, C.; Soranna, D.; D’Araujo, S.C.; Khaldi, A.; Zambon, A.; Parati, G.; Bondue, A.; Vachiéry, J.L. Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a meta-analysis. Eur. Respir. J., 2018, 51(4), 1702427.
[http://dx.doi.org/10.1183/13993003.02427-2017] [PMID: 29439019]
[7]
Bermejo, J.; González-Mansilla, A.; Mombiela, T.; Fernández, A.I.; Martínez-Legazpi, P.; Yotti, R.; García-Orta, R.; Sánchez-Fernández, P.L.; Castaño, M.; Segovia-Cubero, J.; Escribano-Subias, P.; Alberto San Román, J.; Borrás, X.; Alonso-Gómez, A.; Botas, J.; Crespo-Leiro, M.G.; Velasco, S.; Bayés-Genís, A.; López, A.; Muñoz-Aguilera, R.; Jiménez-Navarro, M.; González-Juanatey, J.R.; Evangelista, A.; Elízaga, J.; Martín-Moreiras, J.; González-Santos, J.M.; Moreno-Escobar, E.; Fernández-Avilés, F. Persistent pulmonary hypertension in corrected valvular heart disease: hemodynamic insights and long‐term survival. J. Am. Heart Assoc., 2021, 10(2), e019949.
[http://dx.doi.org/10.1161/JAHA.120.019949] [PMID: 33399006]
[8]
Hunt, S.A.; Abraham, W.T.; Chin, M.H.; Feldman, A.M.; Francis, G.S.; Ganiats, T.G.; Jessup, M.; Konstam, M.A.; Mancini, D.M.; Michl, K.; Oates, J.A.; Rahko, P.S.; Silver, M.A.; Stevenson, L.W.; Yancy, C.W. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. J. Am. Coll. Cardiol., 2009, 53(15), e1-e90.
[http://dx.doi.org/10.1016/j.jacc.2008.11.013] [PMID: 19358937]
[9]
Goldman, L.; Hashimoto, B.; Cook, E.F.; Loscalzo, A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation, 1981, 64(6), 1227-1234.
[http://dx.doi.org/10.1161/01.CIR.64.6.1227] [PMID: 7296795]
[10]
Miller, W.L.; Grill, D.E.; Borlaug, B.A. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JACC Heart Fail., 2013, 1(4), 290-299.
[http://dx.doi.org/10.1016/j.jchf.2013.05.001] [PMID: 24621932]
[11]
Vanderpool, R.R.; Saul, M.; Nouraie, M.; Gladwin, M.T.; Simon, M.A. Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction. JAMA Cardiol., 2018, 3(4), 298-306.
[http://dx.doi.org/10.1001/jamacardio.2018.0128] [PMID: 29541759]
[12]
Crawford, T.C.; Leary, P.J.; Fraser, C.D., III; Suarez-Pierre, A.; Magruder, J.T.; Baumgartner, W.A.; Zehr, K.J.; Whitman, G.J.; Masri, S.C.; Sheikh, F.; De Marco, T.; Maron, B.A.; Sharma, K.; Gilotra, N.A.; Russell, S.D.; Houston, B.A.; Ramu, B.; Tedford, R.J. Impact of the new pulmonary hypertension definition on heart transplant outcomes. Chest, 2020, 157(1), 151-161.
[http://dx.doi.org/10.1016/j.chest.2019.07.028] [PMID: 31446063]
[13]
Benjamin, E.J.; Blaha, M.J.; Chiuve, S.E.; Cushman, M.; Das, S.R.; Deo, R.; de Ferranti, S.D.; Floyd, J.; Fornage, M.; Gillespie, C.; Isasi, C.R.; Jiménez, M.C.; Jordan, L.C.; Judd, S.E.; Lackland, D.; Lichtman, J.H.; Lisabeth, L.; Liu, S.; Longenecker, C.T.; Mackey, R.H.; Matsushita, K.; Mozaffarian, D.; Mussolino, M.E.; Nasir, K.; Neumar, R.W.; Palaniappan, L.; Pandey, D.K.; Thiagarajan, R.R.; Reeves, M.J.; Ritchey, M.; Rodriguez, C.J.; Roth, G.A.; Rosamond, W.D.; Sasson, C.; Towfighi, A.; Tsao, C.W.; Turner, M.B.; Virani, S.S.; Voeks, J.H.; Willey, J.Z.; Wilkins, J.T.; Wu, J.H.Y.; Alger, H.M.; Wong, S.S.; Muntner, P. Heart disease and stroke statistics—2017 update: A report from the american heart association. Circulation, 2017, 135(10), e146-e603.
[http://dx.doi.org/10.1161/CIR.0000000000000485] [PMID: 28122885]
[14]
Dunlay, S.M.; Roger, V.L.; Redfield, M.M. Epidemiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol., 2017, 14(10), 591-602.
[http://dx.doi.org/10.1038/nrcardio.2017.65] [PMID: 28492288]
[15]
Tsao, C.W.; Lyass, A.; Enserro, D.; Larson, M.G.; Ho, J.E.; Kizer, J.R.; Gottdiener, J.S.; Psaty, B.M.; Vasan, R.S. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail., 2018, 6(8), 678-685.
[http://dx.doi.org/10.1016/j.jchf.2018.03.006] [PMID: 30007560]
[16]
Pieske, B.; Tschöpe, C.; de Boer, R.A.; Fraser, A.G.; Anker, S.D.; Donal, E.; Edelmann, F.; Fu, M.; Guazzi, M.; Lam, C.S.P.; Lancellotti, P.; Melenovsky, V.; Morris, D.A.; Nagel, E.; Pieske-Kraigher, E.; Ponikowski, P.; Solomon, S.D.; Vasan, R.S.; Rutten, F.H.; Voors, A.A.; Ruschitzka, F.; Paulus, W.J.; Seferovic, P.; Filippatos, G. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur. Heart J., 2019, 40(40), 3297-3317.
[http://dx.doi.org/10.1093/eurheartj/ehz641] [PMID: 31504452]
[17]
Hoeper, M.M.; Lam, C.S.P.; Vachiery, J.L.; Bauersachs, J.; Gerges, C.; Lang, I.M.; Bonderman, D.; Olsson, K.M.; Gibbs, J.S.R.; Dorfmuller, P.; Guazzi, M.; Galiè, N.; Manes, A.; Handoko, M.L.; Vonk-Noordegraaf, A.; Lankeit, M.; Konstantinides, S.; Wachter, R.; Opitz, C.; Rosenkranz, S. Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. Eur. Heart J., 2016, 38(38), ehw597.
[http://dx.doi.org/10.1093/eurheartj/ehw597] [PMID: 28011705]
[18]
Gerber, Y.; Weston, S.A.; Redfield, M.M.; Chamberlain, A.M.; Manemann, S.M.; Jiang, R.; Killian, J.M.; Roger, V.L. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern. Med., 2015, 175(6), 996-1004.
[http://dx.doi.org/10.1001/jamainternmed.2015.0924] [PMID: 25895156]
[19]
Tedford, R.J.; Hassoun, P.M.; Mathai, S.C.; Girgis, R.E.; Russell, S.D.; Thiemann, D.R.; Cingolani, O.H.; Mudd, J.O.; Borlaug, B.A.; Redfield, M.M.; Lederer, D.J.; Kass, D.A. Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation, 2012, 125(2), 289-297.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.051540] [PMID: 22131357]
[20]
Lam, C.S.P.; Roger, V.L.; Rodeheffer, R.J.; Borlaug, B.A.; Enders, F.T.; Redfield, M.M. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J. Am. Coll. Cardiol., 2009, 53(13), 1119-1126.
[http://dx.doi.org/10.1016/j.jacc.2008.11.051] [PMID: 19324256]
[21]
Aschauer, S.; Zotter-Tufaro, C.; Duca, F.; Kammerlander, A.; Dalos, D.; Mascherbauer, J.; Bonderman, D. Modes of death in patients with heart failure and preserved ejection fraction. Int. J. Cardiol., 2017, 228, 422-426.
[http://dx.doi.org/10.1016/j.ijcard.2016.11.154] [PMID: 27870971]
[22]
Leung, C.C.; Moondra, V.; Catherwood, E.; Andrus, B.W. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am. J. Cardiol., 2010, 106(2), 284-286.
[http://dx.doi.org/10.1016/j.amjcard.2010.02.039] [PMID: 20599017]
[23]
Hoeper, M.M.; Bogaard, H.J.; Condliffe, R.; Frantz, R.; Khanna, D.; Kurzyna, M.; Langleben, D.; Manes, A.; Satoh, T.; Torres, F.; Wilkins, M.R.; Badesch, D.B. Definitions and diagnosis of pulmonary hypertension. J. Am. Coll. Cardiol., 2013, 62(25)(Suppl.), D42-D50.
[http://dx.doi.org/10.1016/j.jacc.2013.10.032] [PMID: 24355641]
[24]
Simonneau, G.; Montani, D.; Celermajer, D.S.; Denton, C.P.; Gatzoulis, M.A.; Krowka, M.; Williams, P.G.; Souza, R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur. Respir. J., 2019, 53(1), 1801913.
[http://dx.doi.org/10.1183/13993003.01913-2018] [PMID: 30545968]
[25]
Naeije, R.; Chin, K. Differentiating precapillary from postcapillary pulmonary hypertension. Circulation, 2019, 140(9), 712-714.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.119.040295] [PMID: 31449453]
[26]
Humbert, M. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J., 2022.
[http://dx.doi.org/10.1183/13993003.00879-2022] [PMID: 36028254]
[27]
Gerges, M.; Gerges, C.; Lang, I.M. How to define pulmonary hypertension due to left heart disease. Eur. Respir. J., 2016, 48(2), 553-555.
[http://dx.doi.org/10.1183/13993003.00432-2016] [PMID: 27174881]
[28]
Gerges, M.; Gerges, C.; Pistritto, A.M.; Lang, M.B.; Trip, P.; Jakowitsch, J.; Binder, T.; Lang, I.M. Pulmonary hypertension in heart failure. Epidemiology, right ventricular function, and survival. Am. J. Respir. Crit. Care Med., 2015, 192(10), 1234-1246.
[http://dx.doi.org/10.1164/rccm.201503-0529OC] [PMID: 26181215]
[29]
Guazzi, M.; Naeije, R. Pulmonary hypertension in heart failure. J. Am. Coll. Cardiol., 2017, 69(13), 1718-1734.
[http://dx.doi.org/10.1016/j.jacc.2017.01.051] [PMID: 28359519]
[30]
Naeije, R.; Gerges, M.; Vachiery, J.L.; Caravita, S.; Gerges, C.; Lang, I.M. Hemodynamic Phenotyping of Pulmonary Hypertension in Left Heart Failure. Circ. Heart Fail., 2017, 10(9), e004082.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.117.004082] [PMID: 28912263]
[31]
Condon, D.F.; Nickel, N.P.; Anderson, R.; Mirza, S.; de Jesus Perez, V.A. The 6th world symposium on pulmonary hypertension: what's old is new. F1000Res, 2019, 8
[http://dx.doi.org/10.12688/f1000research.18811.1]
[32]
Hoeper, M.M.; Dwivedi, K.; Pausch, C.; Lewis, R.A.; Olsson, K.M.; Huscher, D.; Pittrow, D.; Grünig, E.; Staehler, G.; Vizza, C.D.; Gall, H.; Distler, O.; Opitz, C.; Gibbs, J.S.R.; Delcroix, M.; Park, D.H.; Ghofrani, H.A.; Ewert, R.; Kaemmerer, H.; Kabitz, H.J.; Skowasch, D.; Behr, J.; Milger, K.; Lange, T.J.; Wilkens, H.; Seyfarth, H.J.; Held, M.; Dumitrescu, D.; Tsangaris, I.; Vonk-Noordegraaf, A.; Ulrich, S.; Klose, H.; Claussen, M.; Eisenmann, S.; Schmidt, K.H.; Swift, A.J.; Thompson, A.A.R.; Elliot, C.A.; Rosenkranz, S.; Condliffe, R.; Kiely, D.G.; Halank, M. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respir. Med., 2022, 10(10), 937-948.
[http://dx.doi.org/10.1016/S2213-2600(22)00097-2] [PMID: 35777416]
[33]
Hoeper, M.M.; Pausch, C.; Grünig, E.; Klose, H.; Staehler, G.; Huscher, D.; Pittrow, D.; Olsson, K.M.; Vizza, C.D.; Gall, H.; Benjamin, N.; Distler, O.; Opitz, C.; Gibbs, J.S.R.; Delcroix, M.; Ghofrani, H.A.; Rosenkranz, S.; Ewert, R.; Kaemmerer, H.; Lange, T.J.; Kabitz, H.J.; Skowasch, D.; Skride, A.; Jureviciene, E.; Paleviciute, E.; Miliauskas, S.; Claussen, M.; Behr, J.; Milger, K.; Halank, M.; Wilkens, H.; Wirtz, H.; Pfeuffer-Jovic, E.; Harbaum, L.; Scholtz, W.; Dumitrescu, D.; Bruch, L.; Coghlan, G.; Neurohr, C.; Tsangaris, I.; Gorenflo, M.; Scelsi, L.; Vonk-Noordegraaf, A.; Ulrich, S.; Held, M. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J. Heart Lung Transplant., 2020, 39(12), 1435-1444.
[http://dx.doi.org/10.1016/j.healun.2020.09.011] [PMID: 33082079]
[34]
Assad, T.R.; Hemnes, A.R.; Larkin, E.K.; Glazer, A.M.; Xu, M.; Wells, Q.S.; Farber-Eger, E.H.; Sheng, Q.; Shyr, Y.; Harrell, F.E.; Newman, J.H.; Brittain, E.L. Clinical and biological insights into combined post- and precapillary pulmonary hypertension. J. Am. Coll. Cardiol., 2016, 68(23), 2525-2536.
[http://dx.doi.org/10.1016/j.jacc.2016.09.942] [PMID: 27931609]
[35]
Opitz, C.F.; Hoeper, M.M.; Gibbs, J.S.R.; Kaemmerer, H.; Pepke-Zaba, J.; Coghlan, J.G.; Scelsi, L.; D’Alto, M.; Olsson, K.M.; Ulrich, S.; Scholtz, W.; Schulz, U.; Grünig, E.; Vizza, C.D.; Staehler, G.; Bruch, L.; Huscher, D.; Pittrow, D.; Rosenkranz, S. Precapillary, combined, and post-capillary pulmonary hypertension. J. Am. Coll. Cardiol., 2016, 68(4), 368-378.
[http://dx.doi.org/10.1016/j.jacc.2016.05.047] [PMID: 27443433]
[36]
McLaughlin, V.V.; Vachiery, J.L.; Oudiz, R.J.; Rosenkranz, S.; Galiè, N.; Barberà, J.A.; Frost, A.E.; Ghofrani, H.A.; Peacock, A.J.; Simonneau, G.; Rubin, L.J.; Blair, C.; Langley, J.; Hoeper, M.M. Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. J. Heart Lung Transplant., 2019, 38(12), 1286-1295.
[http://dx.doi.org/10.1016/j.healun.2019.09.010] [PMID: 31648845]
[37]
Shah, A.M.; Pfeffer, M.A. The many faces of heart failure with preserved ejection fraction. Nat. Rev. Cardiol., 2012, 9(10), 555-556.
[http://dx.doi.org/10.1038/nrcardio.2012.123] [PMID: 22945329]
[38]
Kao, D.P.; Lewsey, J.D.; Anand, I.S.; Massie, B.M.; Zile, M.R.; Carson, P.E.; McKelvie, R.S.; Komajda, M.; McMurray, J.J.V.; Lindenfeld, J. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur. J. Heart Fail., 2015, 17(9), 925-935.
[http://dx.doi.org/10.1002/ejhf.327] [PMID: 26250359]
[39]
Shah, S.J.; Katz, D.H.; Selvaraj, S.; Burke, M.A.; Yancy, C.W.; Gheorghiade, M.; Bonow, R.O.; Huang, C.C.; Deo, R.C. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation, 2015, 131(3), 269-279.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.114.010637] [PMID: 25398313]
[40]
Tang, W.H.W.; Wilcox, J.D.; Jacob, M.S.; Rosenzweig, E.B.; Borlaug, B.A.; Frantz, R.P.; Hassoun, P.M.; Hemnes, A.R.; Hill, N.S.; Horn, E.M.; Singh, H.S.; Systrom, D.M.; Tedford, R.J.; Vanderpool, R.R.; Waxman, A.B.; Xiao, L.; Leopold, J.A.; Rischard, F.P. Comprehensive diagnostic evaluation of cardiovascular physiology in patients with pulmonary vascular disease. Circ. Heart Fail., 2020, 13(3), e006363.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.119.006363] [PMID: 32088984]
[41]
Hemnes, A.R.; Beck, G.J.; Newman, J.H.; Abidov, A.; Aldred, M.A.; Barnard, J.; Berman Rosenzweig, E.; Borlaug, B.A.; Chung, W.K.; Comhair, S.A.A.; Erzurum, S.C.; Frantz, R.P.; Gray, M.P.; Grunig, G.; Hassoun, P.M.; Hill, N.S.; Horn, E.M.; Hu, B.; Lempel, J.K.; Maron, B.A.; Mathai, S.C.; Olman, M.A.; Rischard, F.P.; Systrom, D.M.; Tang, W.H.W.; Waxman, A.B.; Xiao, L.; Yuan, J.X.J.; Leopold, J.A. PVDOMICS: A multi-center study to improve understanding of pulmonary vascular disease through phenomics. Circ. Res., 2017, 121(10), 1136-1139.
[http://dx.doi.org/10.1161/CIRCRESAHA.117.311737] [PMID: 29074534]
[42]
Benza, R.L.; Gomberg-Maitland, M.; Demarco, T.; Frost, A.E.; Torbicki, A.; Langleben, D.; Pulido, T.; Correa-Jaque, P.; Passineau, M.J.; Wiener, H.W.; Tamari, M.; Hirota, T.; Kubo, M.; Tiwari, H.K. Endothelin-1 pathway polymorphisms and outcomes in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med., 2015, 192(11), 1345-1354.
[http://dx.doi.org/10.1164/rccm.201501-0196OC] [PMID: 26252367]
[43]
Haddad, F.; Ataam, J.A.; Amsallem, M.; Cauwenberghs, N.; Kuznetsova, T.; Rosenberg-Hasson, Y.; Zamanian, R.T.; Karakikes, I.; Horne, B.D.; Muhlestein, J.B.; Kwee, L.; Shah, S.; Maecker, H.; Knight, S.; Knowlton, K. Insulin growth factor phenotypes in heart failure with preserved ejection fraction, an INSPIRE registry and CATHGEN study. J. Card. Fail., 2022, 28(6), 935-946.
[http://dx.doi.org/10.1016/j.cardfail.2021.12.012] [PMID: 34979242]
[44]
Sweatt, A.J.; Hedlin, H.K.; Balasubramanian, V.; Hsi, A.; Blum, L.K.; Robinson, W.H.; Haddad, F.; Hickey, P.M.; Condliffe, R.; Lawrie, A.; Nicolls, M.R.; Rabinovitch, M.; Khatri, P.; Zamanian, R.T. Discovery of distinct immune phenotypes using machine learning in pulmonary arterial hypertension. Circ. Res., 2019, 124(6), 904-919.
[http://dx.doi.org/10.1161/CIRCRESAHA.118.313911] [PMID: 30661465]
[45]
Mickael, C.; Kheyfets, V.O.; Langouët-Astrié, C.; Lee, M.H.; Sanders, L.A.; Trentin, C.O.; Sweatt, A.J.; Zamanian, R.T.; Bull, T.M.; Stenmark, K.; Graham, B.B.; Tuder, R.M. Peripheral blood inflammation profile of patients with pulmonary arterial hypertension using the high-throughput olink proteomics platform. Am. J. Respir. Cell Mol. Biol., 2022, 66(5), 580-581.
[http://dx.doi.org/10.1165/rcmb.2021-0369LE] [PMID: 35486078]
[46]
Humbert, M.; Guignabert, C.; Bonnet, S.; Dorfmüller, P.; Klinger, J.R.; Nicolls, M.R.; Olschewski, A.J.; Pullamsetti, S.S.; Schermuly, R.T.; Stenmark, K.R.; Rabinovitch, M. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur. Respir. J., 2019, 53(1), 1801887.
[http://dx.doi.org/10.1183/13993003.01887-2018] [PMID: 30545970]
[47]
Hunt, J.M.; Bethea, B.; Liu, X.; Gandjeva, A.; Mammen, P.P.A.; Stacher, E.; Gandjeva, M.R.; Parish, E.; Perez, M.; Smith, L.; Graham, B.B.; Kuebler, W.M.; Tuder, R.M. Pulmonary veins in the normal lung and pulmonary hypertension due to left heart disease. Am. J. Physiol. Lung Cell. Mol. Physiol., 2013, 305(10), L725-L736.
[http://dx.doi.org/10.1152/ajplung.00186.2013] [PMID: 24039255]
[48]
Tuder, R.M. Pulmonary vascular remodeling in pulmonary hypertension. Cell Tissue Res., 2017, 367(3), 643-649.
[http://dx.doi.org/10.1007/s00441-016-2539-y] [PMID: 28025704]
[49]
Stacher, E.; Graham, B.B.; Hunt, J.M.; Gandjeva, A.; Groshong, S.D.; McLaughlin, V.V.; Jessup, M.; Grizzle, W.E.; Aldred, M.A.; Cool, C.D.; Tuder, R.M. Modern age pathology of pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med., 2012, 186(3), 261-272.
[http://dx.doi.org/10.1164/rccm.201201-0164OC] [PMID: 22679007]
[50]
Chazova, I.; Loyd, J.E.; Zhdanov, V.S.; Newman, J.H.; Belenkov, Y.; Meyrick, B. Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. Am. J. Pathol., 1995, 146(2), 389-397.
[PMID: 7856750]
[51]
Dorfmüller, P.; Humbert, M.; Perros, F.; Sanchez, O.; Simonneau, G.; Müller, K.M.; Capron, F. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum. Pathol., 2007, 38(6), 893-902.
[http://dx.doi.org/10.1016/j.humpath.2006.11.022] [PMID: 17376507]
[52]
Wagenvoort, C.A.; Wagenvoort, N. The pulmonary vasculature in normal cattle at sea level at different ages. Pathol. Eur., 1969, 4(3), 265-273.
[PMID: 4104260]
[53]
Wagenvoort, C.A.; Nauta, J.; Van Der Schaar, P.J.; Weeda, H.W.H.; Wagenvoort, N. The pulmonary vasculature in complete transpossition of the greatvessels, judged from lung biopsies. Circulation, 1968, 38(4), 746-754.
[http://dx.doi.org/10.1161/01.CIR.38.4.746] [PMID: 5677959]
[54]
Galambos, C.; Sims-Lucas, S.; Abman, S.H.; Cool, C.D. Intrapulmonary Bronchopulmonary Anastomoses and Plexiform Lesions in Idiopathic Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med., 2016, 193(5), 574-576.
[http://dx.doi.org/10.1164/rccm.201507-1508LE] [PMID: 26930433]
[55]
Dixon, D.L.; Mayne, G.C.; Griggs, K.M.; de Pasquale, C.G.; Bersten, A.D. Chronic elevation of pulmonary microvascular pressure in chronic heart failure reduces bi-directional pulmonary fluid flux. Eur. J. Heart Fail., 2013, 15(4), 368-375.
[http://dx.doi.org/10.1093/eurjhf/hfs201] [PMID: 23248216]
[56]
Fayyaz, A.U.; Edwards, W.D.; Maleszewski, J.J.; Konik, E.A.; DuBrock, H.M.; Borlaug, B.A.; Frantz, R.P.; Jenkins, S.M.; Redfield, M.M. Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation, 2018, 137(17), 1796-1810.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.031608] [PMID: 29246894]
[57]
Lai, Y.C.; Wang, L.; Gladwin, M.T. Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction. J. Physiol., 2019, 597(4), 1143-1156.
[http://dx.doi.org/10.1113/JP275858] [PMID: 30549058]
[58]
Delgado, J.F.; Conde, E.; Sánchez, V.; López-Ríos, F.; Gómez-Sánchez, M.A.; Escribano, P.; Sotelo, T.; de la Cámara, A.G.; Cortina, J.; de la Calzada, C.S. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur. J. Heart Fail., 2005, 7(6), 1011-1016.
[http://dx.doi.org/10.1016/j.ejheart.2004.10.021] [PMID: 16227139]
[59]
Melenovsky, V.; Hwang, S.J.; Lin, G.; Redfield, M.M.; Borlaug, B.A. Right heart dysfunction in heart failure with preserved ejection fraction. Eur. Heart J., 2014, 35(48), 3452-3462.
[http://dx.doi.org/10.1093/eurheartj/ehu193] [PMID: 24875795]
[60]
Shah, A.M.; Claggett, B.; Sweitzer, N.K.; Shah, S.J.; Anand, I.S.; O’Meara, E.; Desai, A.S.; Heitner, J.F.; Li, G.; Fang, J.; Rouleau, J.; Zile, M.R.; Markov, V.; Ryabov, V.; Reis, G.; Assmann, S.F.; McKinlay, S.M.; Pitt, B.; Pfeffer, M.A.; Solomon, S.D. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ. Heart Fail., 2014, 7(5), 740-751.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.114.001583] [PMID: 25122186]
[61]
Gorter, T.M.; Rienstra, M.; van Veldhuisen, D.J. Right ventricular dysfunction in heart failure with reduced vs. preserved ejection fraction: non-identical twins? Eur. J. Heart Fail., 2017, 19(7), 880-882.
[http://dx.doi.org/10.1002/ejhf.691] [PMID: 27860059]
[62]
Borlaug, B.A.; Melenovsky, V.; Koepp, K.E. Inhaled sodium nitrite improves rest and exercise hemodynamics in heart failure with preserved ejection fraction. Circ. Res., 2016, 119(7), 880-886.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.309184] [PMID: 27458234]
[63]
Vonk Noordegraaf, A.; Westerhof, B.E.; Westerhof, N. The relationship between the right ventricle and its load in pulmonary hypertension. J. Am. Coll. Cardiol., 2017, 69(2), 236-243.
[http://dx.doi.org/10.1016/j.jacc.2016.10.047] [PMID: 28081831]
[64]
Obokata, M.; Reddy, Y.N.V.; Melenovsky, V.; Pislaru, S.; Borlaug, B.A. Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur. Heart J., 2019, 40(8), 689-697.
[http://dx.doi.org/10.1093/eurheartj/ehy809] [PMID: 30544228]
[65]
Bianco, C.M.; Farjo, P.D.; Ghaffar, Y.A.; Sengupta, P.P. Myocardial mechanics in patients with normal LVEF and diastolic dysfunction. JACC Cardiovasc. Imaging, 2020, 13(1), 258-271.
[http://dx.doi.org/10.1016/j.jcmg.2018.12.035] [PMID: 31202770]
[66]
Hemnes, A.R.; Brittain, E.L.; Trammell, A.W.; Fessel, J.P.; Austin, E.D.; Penner, N.; Maynard, K.B.; Gleaves, L.; Talati, M.; Absi, T.; DiSalvo, T.; West, J. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med., 2014, 189(3), 325-334.
[http://dx.doi.org/10.1164/rccm.201306-1086OC] [PMID: 24274756]
[67]
Ruffenach, G.; Chabot, S.; Tanguay, V.F.; Courboulin, A.; Boucherat, O.; Potus, F.; Meloche, J.; Pflieger, A.; Breuils-Bonnet, S.; Nadeau, V.; Paradis, R.; Tremblay, E.; Girerd, B.; Hautefort, A.; Montani, D.; Fadel, E.; Dorfmuller, P.; Humbert, M.; Perros, F.; Paulin, R.; Provencher, S.; Bonnet, S. Role for runt-related transcription factor 2 in proliferative and calcified vascular lesions in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med., 2016, 194(10), 1273-1285.
[http://dx.doi.org/10.1164/rccm.201512-2380OC] [PMID: 27149112]
[68]
Tanguay, V.F.; Babin, C.; Giardetti, G.; Sohier-Poirier, C.; Ménard-Cholette, V.; Ranchoux, B.; Ruffenach, G.; Montani, D.; Bonnet, S.; Provencher, S. Enhanced pulmonary artery radiodensity in pulmonary arterial hypertension: a sign of early calcification? Am. J. Respir. Crit. Care Med., 2019, 199(6), 799-802.
[http://dx.doi.org/10.1164/rccm.201806-1027LE] [PMID: 30571924]
[69]
Kramer, T.; Dumitrescu, D.; Gerhardt, F.; Orlova, K.; ten Freyhaus, H.; Hellmich, M.; Baldus, S.; Rosenkranz, S. Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and precapillary pulmonary hypertension. Int. J. Cardiol., 2019, 283, 152-158.
[http://dx.doi.org/10.1016/j.ijcard.2018.12.078] [PMID: 30777406]
[70]
Guazzi, M.; Vicenzi, M.; Arena, R.; Guazzi, M.D. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation, 2011, 124(2), 164-174.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.983866] [PMID: 21709061]
[71]
Hoendermis, E.S.; Liu, L.C.Y.; Hummel, Y.M.; van der Meer, P.; de Boer, R.A.; Berger, R.M.F.; van Veldhuisen, D.J.; Voors, A.A. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur. Heart J., 2015, 36(38), 2565-2573.
[http://dx.doi.org/10.1093/eurheartj/ehv336] [PMID: 26188003]
[72]
Vachiéry, J.L.; Delcroix, M.; Al-Hiti, H.; Efficace, M.; Hutyra, M.; Lack, G.; Papadakis, K.; Rubin, L.J. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur. Respir. J., 2018, 51(2), 1701886.
[http://dx.doi.org/10.1183/13993003.01886-2017] [PMID: 29437943]
[73]
Koller, B.; Steringer-Mascherbauer, R.; Ebner, C.H.; Weber, T.; Ammer, M.; Eichinger, J.; Pretsch, I.; Herold, M.; Schwaiger, J.; Ulmer, H.; Grander, W. Pilot Study of Endothelin Receptor Blockade in Heart Failure with Diastolic Dysfunction and Pulmonary Hypertension (BADDHY-Trial). Heart Lung Circ., 2017, 26(5), 433-441.
[http://dx.doi.org/10.1016/j.hlc.2016.09.004] [PMID: 27816421]
[74]
Ichinose, F.; Roberts, J.D., Jr; Zapol, W.M. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation, 2004, 109(25), 3106-3111.
[http://dx.doi.org/10.1161/01.CIR.0000134595.80170.62] [PMID: 15226227]
[75]
Borlaug, B.A.; Koepp, K.E.; Melenovsky, V. Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction. J. Am. Coll. Cardiol., 2015, 66(15), 1672-1682.
[http://dx.doi.org/10.1016/j.jacc.2015.07.067] [PMID: 26449137]
[76]
Simon, M.A.; Vanderpool, R.R.; Nouraie, M.; Bachman, T.N.; White, P.M.; Sugahara, M.; Gorcsan, J., III; Parsley, E.L.; Gladwin, M.T. Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction. JCI Insight, 2016, 1(18), e89620.
[http://dx.doi.org/10.1172/jci.insight.89620] [PMID: 27812547]
[77]
Belyavskiy, E.; Ovchinnikov, A.; Potekhina, A.; Ageev, F.; Edelmann, F. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study. BMC Cardiovasc. Disord., 2020, 20(1), 408.
[http://dx.doi.org/10.1186/s12872-020-01671-2] [PMID: 32912157]
[78]
Redfield, M.M.; Chen, H.H.; Borlaug, B.A.; Semigran, M.J.; Lee, K.L.; Lewis, G.; LeWinter, M.M.; Rouleau, J.L.; Bull, D.A.; Mann, D.L.; Deswal, A.; Stevenson, L.W.; Givertz, M.M.; Ofili, E.O.; O’Connor, C.M.; Felker, G.M.; Goldsmith, S.R.; Bart, B.A.; McNulty, S.E.; Ibarra, J.C.; Lin, G.; Oh, J.K.; Patel, M.R.; Kim, R.J.; Tracy, R.P.; Velazquez, E.J.; Anstrom, K.J.; Hernandez, A.F.; Mascette, A.M.; Braunwald, E.; RELAX Trial, Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA, 2013, 309(12), 1268-1277.
[http://dx.doi.org/10.1001/jama.2013.2024] [PMID: 23478662]
[79]
Bonderman, D.; Pretsch, I.; Steringer-Mascherbauer, R.; Jansa, P.; Rosenkranz, S.; Tufaro, C.; Bojic, A.; Lam, C.S.P.; Frey, R.; Ochan Kilama, M.; Unger, S.; Roessig, L.; Lang, I.M. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest, 2014, 146(5), 1274-1285.
[http://dx.doi.org/10.1378/chest.14-0106] [PMID: 24991733]
[80]
Dachs, T.M.; Duca, F.; Rettl, R.; Binder-Rodriguez, C.; Dalos, D.; Ligios, L.C.; Kammerlander, A.; Grünig, E.; Pretsch, I.; Steringer-Mascherbauer, R.; Ablasser, K.; Wargenau, M.; Mascherbauer, J.; Lang, I.M.; Hengstenberg, C.; Badr-Eslam, R.; Kastner, J.; Bonderman, D. Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial. Eur. Heart J., 2022, 43(36), 3402-3413.
[http://dx.doi.org/10.1093/eurheartj/ehac389] [PMID: 35909264]
[81]
Al-Naamani, N.; Preston, I.R.; Paulus, J.K.; Hill, N.S.; Roberts, K.E. Pulmonary arterial capacitance is an important predictor of mortality in heart failure with a preserved ejection fraction. JACC Heart Fail., 2015, 3(6), 467-474.
[http://dx.doi.org/10.1016/j.jchf.2015.01.013] [PMID: 26046840]
[82]
O’Sullivan, C.J.; Wenaweser, P.; Ceylan, O.; Rat-Wirtzler, J.; Stortecky, S.; Heg, D.; Spitzer, E.; Zanchin, T.; Praz, F.; Tüller, D.; Huber, C.; Pilgrim, T.; Nietlispach, F.; Khattab, A.A.; Carrel, T.; Meier, B.; Windecker, S.; Buellesfeld, L. Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation. Circ. Cardiovasc. Interv., 2015, 8(7), e002358.
[http://dx.doi.org/10.1161/CIRCINTERVENTIONS.114.002358] [PMID: 26156149]
[83]
Heinzel, F.R.; Shah, S.J. The future of heart failure with preserved ejection fraction. Herz, 2022, 47(4), 308-323.
[http://dx.doi.org/10.1007/s00059-022-05124-8] [PMID: 35767073]
[84]
Broughton, K.M.; Sussman, M.A. Empowering adult stem cells for myocardial regeneration V2.0. Circ. Res., 2016, 118(5), 867-880.
[http://dx.doi.org/10.1161/CIRCRESAHA.115.305227] [PMID: 26941423]
[85]
Fernández-Avilés, F.; Sanz-Ruiz, R.; Climent, A.M.; Badimon, L.; Bolli, R.; Charron, D.; Fuster, V.; Janssens, S.; Kastrup, J.; Kim, H.S.; Lüscher, T.F.; Martin, J.F.; Menasché, P.; Simari, R.D.; Stone, G.W.; Terzic, A.; Willerson, J.T.; Wu, J.C.; Fernández-Avilés, F.; Terzic, A.; Badimon, L.; Broughton, K.; DiFede, D.L.; Dimmeler, S.; Madonna, R.; Penn, M.S.; Sussman, M.A.; Sluijter, J.P.G.; Wollert, K.C.; Balkan, W.; Bolli, R.; Chamuleau, S.; Charron, D.; Fernández-Santos, M.E.; Fuster, V.; Goliasch, G.; Gyöngyösi, M.; Hare, J.M.; Lüscher, T.F.; Tompkins, B.A.; Winkler, J.; Bayés-Genís, A.; Henry, T.D.; Taylor, D.A.; Climent, A.M.; Lerman, A.; Pelacho, B.; Prosper, F.; Sanz-Ruiz, R.; Perin, E.C.; Pompilio, G.; Gersh, B.; Bartunek, J.; Duckers, E.; Ferdinandy, P.; Janssens, S.; Losordo, D.W.; Sánchez, P.L.; Sherman, W.; Wojakowski, W.; Zeiher, A.; Kastrup, J.; Roncalli, J.; Mathur, A.; Crea, F.; D´Amario, D.; Povsic, T.J.; Traverse, J.; Ylä-Herttuala, S. Global position paper on cardiovascular regenerative medicine. Eur. Heart J., 2017, 38(33), 2532-2546.
[http://dx.doi.org/10.1093/eurheartj/ehx248] [PMID: 28575280]
[86]
Wan, Z.; Zhao, L.; Lu, F.; Gao, X.; Dong, Y.; Zhao, Y.; Wei, M.; Yang, G.; Xing, C.; Liu, L. Mononuclear phagocyte system blockade improves therapeutic exosome delivery to the myocardium. Theranostics, 2020, 10(1), 218-230.
[http://dx.doi.org/10.7150/thno.38198] [PMID: 31903116]
[87]
Gao, L.; Wang, L.; Wei, Y.; Krishnamurthy, P.; Walcott, G.P.; Menasché, P.; Zhang, J. Exosomes secreted by hiPSC-derived cardiac cells improve recovery from myocardial infarction in swine. Sci. Transl. Med., 2020, 12(561), eaay1318.
[http://dx.doi.org/10.1126/scitranslmed.aay1318] [PMID: 32938792]
[88]
Jung, J.H.; Fu, X.; Yang, P.C. Exosomes generated from iPSC-derivatives. Circ. Res., 2017, 120(2), 407-417.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.309307] [PMID: 28104773]